Skip to main content

Table 3 Dosimetric comparison of VMATAuto and VMATClinical for institution A and B (mean ± standard deviation)

From: Multi-institutional evaluation of a Pareto navigation guided automated radiotherapy planning solution for prostate cancer

  

Institution A

Institution B

Metric

VMATAuto

VMATClinical

p value

VMATAuto

VMATClinical

p value

PTV60

D98% (Gy)

58.8 ± 0.1

59.0 ± 0.2

0.00

59.0 ± 0.1

58.7 ± 0.3

0.00

 

D99% (Gy)

58.7 ± 0.1

58.8 ± 0.3

0.03

58.9 ± 0.1

58.5 ± 0.4

0.00

 

D2% (Gy)

61.3 ± 0.1

60.8 ± 0.3

0.00

61.0 ± 0.1

60.9 ± 0.4

0.68

 

CI

0.562 ± 0.027

0.570 ± 0.041

0.31

0.601 ± 0.031

0.636 ± 0.042

0.00

 

HI

0.041 ± 0.002

0.030 ± 0.007

0.00

0.032 ± 0.002

0.037 ± 0.009

0.03

PTV57.5

D98% (Gy)*

55.9 ± 0.1

55.5 ± 0.9

0.06

55.7 ± 0.2

54.7 ± 0.2

0.00

 

D99% (Gy)

56.0 ± 0.2

55.6 ± 0.9

0.07

55.9 ± 0.2

54.9 ± 0.2

0.00

 

D2% (Gy)*

59.9 ± 0.1

60.2 ± 0.4

0.02

60.3 ± 0.1

60.1 ± 0.5

0.18

 

CI

0.827 ± 0.013

0.862 ± 0.043

0.00

0.845 ± 0.013

0.863 ± 0.040

0.02

 

HI*

0.068 ± 0.004

0.080 ± 0.014

0.00

0.077 ± 0.004

0.093 ± 0.009

0.00

PTV48

D98% (Gy)*

46.5 ± 0.3

45.8 ± 0.5

0.00

46.5 ± 0.2

45.5 ± 0.7

0.00

 

D99% (Gy)

47.1 ± 0.7

46.5 ± 0.9

0.00

47.1 ± 0.8

46.4 ± 1.0

0.00

 

D2% (Gy)*

57.0 ± 0.4

57.3 ± 0.9

0.37

57.2 ± 0.3

56.5 ± 0.9

0.01

 

CI

0.707 ± 0.017

0.745 ± 0.033

0.00

0.698 ± 0.021

0.683 ± 0.044

0.23

 

HI*

0.206 ± 0.007

0.224 ± 0.015

0.00

0.211 ± 0.005

0.219 ± 0.020

0.17

Rectum

V24.3Gy (%)

47.2 ± 13.0

62.3 ± 10.4

0.00

51.9 ± 11.6

60.3 ± 10.3

0.00

 

V32.4Gy (%)

32.9 ± 12.1

44.1 ± 11.5

0.00

38.6 ± 10.9

43.6 ± 9.9

0.00

 

V40.5Gy (%)

23.0 ± 9.1

26.5 ± 8.9

0.00

28.2 ± 8.8

29.7 ± 8.4

0.05

 

V48.6Gy (%)

13.6 ± 4.3

14.5 ± 5.3

0.17

15.9 ± 4.4

15.8 ± 5.0

0.79

 

V52.7Gy (%)

9.5 ± 2.8

10.4 ± 3.8

0.16

10.1 ± 3.0

10.4 ± 3.9

0.50

 

V56.8Gy (%)

3.9 ± 1.6

6.4 ± 2.6

0.00

4.8 ± 2.0

5.5 ± 2.3

0.00

 

V60.0Gy (%)

0.0 ± 0.0

0.3 ± 0.4

0.00

0.0 ± 0.1

0.3 ± 0.4

0.00

 

DMean (Gy)

25.3 ± 4.7

29.0 ± 4.3

0.00

28.3 ± 4.1

30.1 ± 3.3

0.00

Bladder

V40.5Gy (%)

25.3 ± 14.7

24.0 ± 14.1

0.00

15.5 ± 7.4

16.4 ± 7.4

0.01

 

V48.6Gy (%)

18.5 ± 11.3

17.9 ± 11.1

0.02

10.7 ± 5.9

11.4 ± 5.6

0.02

 

V60.0Gy (%)

1.8 ± 1.6

2.3 ± 1.7

0.07

1.2 ± 0.9

1.1 ± 0.8

0.65

 

DMean (Gy)

24.3 ± 9.3

23.8 ± 9.2

0.20

17.4 ± 5.3

18.7 ± 5.7

0.00

Bowel

V40.5Gy (cm3)

   

0.8 ± 1.8

0.8 ± 1.6

n < 10

Femoral Head (Lt)

V40.5Gy (%)

   

0.0 ± 0.0

0.0 ± 0.1

n < 10

Femoral Head (Rt)

V40.5Gy (%)

   

0.0 ± 0.0

0.0 ± 0.0

n < 10

External

D1.8cm3 (Gy)

61.2 ± 0.1

60.8 ± 0.2

0.00

61.0 ± 0.1

61.0 ± 0.4

0.88

External

V5.0Gy (%)

34.8 ± 6.1

32.5 ± 6.0

0.00

27.2 ± 2.7

27.4 ± 2.8

0.17

Beam MU

MU

637 ± 36

570 ± 37

0.00

739 ± 53

640 ± 118

0.01

Plan Ranking vs VMATClinical

Plans Superior (%)

90%

65%

 

Plans Equivalent (%)

0%

30% (35%)

 

Plans Inferior (%)

10%

5% (0%)

  1. Results in bold indicate statistically significant differences (p < = 0.05). Dosimetrist plan rankings are provided in parenthesis where preference differs from the oncologist
  2. CI: Paddick’s Conformity Index for the specified PTV.
  3. HI: homogeneity index for the specified PTV
  4. *Higher prescription PTV(s) subtracted from PTV when reporting